Wegovy for MASH (Fatty Liver): The New FDA Approval

On August 15, 2025, the FDA approved Wegovy (semaglutide 2.4 mg) for a new indication: noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) — the serious, inflammatory form of fatty liver disease — in adults with moderate-to-advanced liver fibrosis¹. It made semaglutide the first GLP-1 medicine cleared for a liver indication, and only the second drug of any kind approved for MASH. That is genuinely a big deal. But the headlines ("Wegovy now treats fatty liver") flatten two distinctions that matter a great deal if this might apply to you: the approval is narrow, and it rests on histology, not yet on proven hard outcomes. This article walks through exactly what was approved, on what evidence, and where the honest limits are.

What MASH is — and why it's not just "fatty liver"

Fatty liver is a spectrum. At the mild end is simple steatosis — fat in the liver without much inflammation or scarring. MASH (formerly called NASH) is further along: fat plus active inflammation and liver-cell injury, which over years can drive fibrosis (scarring) and, in some people, cirrhosis and liver failure². The naming was formally updated in 2023 — "NAFLD/NASH" became "MASLD/MASH" under a multi-society consensus, so you'll see both sets of terms in older sources². The reason MASH matters clinically is the fibrosis: how scarred the liver is (staged F0 to F4, where F4 is cirrhosis) is the strongest predictor of bad liver outcomes. That staging is the key to understanding exactly who this approval covers.

What the FDA actually approved

The indication is precise. Wegovy is approved for noncirrhotic MASH with moderate-to-advanced fibrosis — fibrosis stages F2 to F3 — used together with a reduced-calorie diet and increased physical activity³. Three words in that sentence do real work:

• •Noncirrhotic — it is not approved for people who already have cirrhosis (F4). We'll come back to why that exclusion is evidence-based, not arbitrary.
• •Moderate-to-advanced fibrosis (F2-F3) — it is also not approved for fatty liver with little or no scarring (F0-F1). The trial that supports it enrolled people with established fibrosis.
• •Accelerated approval — this is the regulatory category that matters most for honest framing. The FDA granted it under the accelerated approval pathway, which lets a drug reach patients based on a marker reasonably likely to predict benefit (here, improvement in MASH and fibrosis on biopsy) before the long-term outcome data are in. The label says so explicitly: continued approval "may be contingent upon the verification and description of clinical benefit in a confirmatory trial"³.

The evidence: the ESSENCE trial, part 1

The approval is built on ESSENCE (NCT04822181), an ongoing phase 3, double-blind, randomized, placebo-controlled trial that assigned 1,197 patients with biopsy-confirmed MASH and fibrosis stage F2 or F3 to once-weekly semaglutide 2.4 mg or placebo⁴. The full trial runs 240 weeks; what supported the 2025 approval is a planned interim analysis ("part 1") in the first 800 patients at week 72⁴.

On the two co-primary histology endpoints, semaglutide clearly beat placebo⁴:

• •Resolution of steatohepatitis without worsening of fibrosis: 62.9% on semaglutide vs 34.3% on placebo (a 28.7-percentage-point difference).
• •Reduction in liver fibrosis without worsening of steatohepatitis: 36.8% vs 22.4% (a 14.4-point difference).

Both results were highly statistically significant. A combined endpoint — both MASH resolution and fibrosis improvement in the same patient — was met by 32.7% on semaglutide vs 16.1% on placebo⁴. As you'd expect, weight came down too: mean body-weight change was −10.5% with semaglutide vs −2.0% with placebo⁴. This builds on an earlier phase 2 semaglutide trial in NASH that had already shown a dose-dependent improvement in steatohepatitis resolution⁵ — ESSENCE is the larger, fibrosis-staged confirmation.

The honest limit: histology improvement is not the same as proven hard outcomes

This is the single most important framing in the whole article, and it's where most coverage gets sloppy.

What ESSENCE part 1 proved is that semaglutide improves the liver biopsy — it resolves the steatohepatitis and reduces the fibrosis stage in a meaningful share of patients, more than placebo⁴. Those are surrogate (histologic) endpoints. They are reasonably expected to predict benefit, which is exactly why accelerated approval was granted on them.

What ESSENCE part 1 did not prove is that semaglutide reduces the outcomes patients actually care about: progression to cirrhosis, liver failure, liver transplant, liver cancer, or death. Those "hard" clinical outcomes are the job of part 2 of the same trial, which reads out at the full 240 weeks — expected around 2029⁴. Until then, the benefit on hard outcomes is expected, not demonstrated. That's not a knock on the drug; it's just what accelerated approval means, and the label's confirmatory-trial language³ makes the same point. Separating "the biopsy got better" from "people lived longer or avoided cirrhosis" is the honest way to read this approval.

Why cirrhosis (F4) is excluded — and it's not a footnote

The cirrhosis exclusion isn't regulatory caution for its own sake. It reflects a real, separate trial. A phase 2 study tested the same semaglutide 2.4 mg specifically in people with NASH-related compensated cirrhosis — and after 48 weeks, semaglutide did not significantly improve fibrosis or achieve NASH resolution versus placebo⁶. In other words, the benefit that shows up at F2-F3 did not show up once scarring had progressed to cirrhosis. So if you already have cirrhosis, the data simply don't support using Wegovy to reverse it, and the FDA indication correctly stops short of F4³⁶. People with fatty liver but no meaningful fibrosis (F0-F1) are likewise outside the studied — and approved — population.

What this means if you might be a candidate

A few practical, honest takeaways:

• •You need a real diagnosis. The approval is for biopsy-defined (or otherwise rigorously staged) MASH with F2-F3 fibrosis — not for a fatty liver casually noted on an ultrasound. Establishing where you actually sit on the F0-F4 scale is the first step, and that's a hepatology conversation.
• •It's the same drug and dose you may know for weight loss. This is Wegovy 2.4 mg, the same molecule and titration used for obesity — so the side-effect profile is the familiar GLP-1 one (mostly gastrointestinal; gallbladder and other class effects also apply — see semaglutide and your gallbladder & kidneys and the full dosing & side-effects guide). The MASH approval doesn't introduce a new safety story so much as a new indication for a well-characterized drug.
• •Weight loss is part of the mechanism, not a coincidence. The ~10.5% weight reduction in ESSENCE tracks with the liver improvement⁴; metabolic-driven MASH responds to metabolic treatment. That's also why diet and physical activity are written into the indication³, not treated as optional.
• •This is a prescription medicine with a narrow license. It is not a reason to seek semaglutide for "liver detox" or mild fatty liver. The proven benefit lives inside the F2-F3, noncirrhotic window.

Semaglutide's expanding evidence base — weight, cardiovascular risk, and now liver histology — is a genuine story, but each indication stands on its own trial in its own population. For the cardiovascular side of that ledger, see do Wegovy & Ozempic protect the heart?. For the complete picture of how the drug works, what to expect, and the full safety profile, start with our pillar guide, Semaglutide: how it works, results & side effects. And if you're weighing where to get it, our editorial ranking is at the best semaglutide options, rated.

The bottom line

In August 2025 the FDA gave Wegovy accelerated approval for noncirrhotic MASH with moderate-to-advanced (F2-F3) fibrosis, on the strength of ESSENCE part 1, where semaglutide roughly doubled the rate of steatohepatitis resolution and meaningfully improved fibrosis versus placebo at 72 weeks¹⁴. That is a real, randomized, FDA-recognized liver benefit — on biopsy. What it is not, yet, is proof that the drug prevents cirrhosis, liver failure, or death; those outcomes await ESSENCE part 2 around 2029⁴. And it does not extend to people who already have cirrhosis, where a dedicated trial found no significant benefit⁶. Read this approval for exactly what it is: an important first GLP-1 win in fatty-liver disease, with the honest asterisk that the histology has improved and the long-term outcomes are still being measured.